ベリノスタット(PXD-101) 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, ヒストン脱アセチル化酵素阻害薬
説明
Belinostat is a drug which was developed by Spectrum Pharmaceuticals
and is currently marketed by Onxeo as Beleodaq®. The
drug, which received fast track designation by the United States
Food and Drug Administration (US FDA) and was approved for
the treatment of hematological malignancies and solid tumors
associated with peripheral T-cell lymphoma (PTCL) in 2014, is a
histone deacetylase (HDAC) inhibitor and is the third such treatment
to receive accelerated approval for PTCL, the others being
vorinostat (Zolinza®) and pralatrexate (Folotyn®). Although belinostat
was not yet approved in Europe as of August 2014, the
compound exhibits a safety profile considered to be acceptable
for HDAC inhibitors–less than 25% of patients reported adverse
effects and these most frequently were nausea, fatigue, pyrexia,
anemia, and emesis.
使用
Belinostat is a novel histone deacetylase 3 selective inhibitor, which protects the β cells from cytokine-induced apoptosis.
定義
ChEBI: A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
ベリノスタット(PXD-101) 上流と下流の製品情報
原材料
準備製品